But it was only after a description of a carisoprodol intoxication in 1976 .
Today, there are several concerns regarding carisoprodol, because it was approved for marketing before the FDA required that safety and efficacy be proved in clinical studies.
Berger at Wallace laboratories on the basis of meprobamate, hoping that it would have better muscle-relaxing properties, less abuse potential, and safer in overdose than meprobamate .
The metabolism of carisoprodol to meprobamate was described in mice in 1969.
Consult your doctor or pharmacist for more details, and report any withdrawal reactions right away.
Meprobamate is another schedule IV drug that is rarely used because 1) not much drug is needed to overdose; 2) it is psychologically habit-forming; 3) stopping it can cause severe, life-threatening physical withdrawal, and 4) it can make the sedating effects of other medications, like opioid pain killers, much stronger, potentially leading to death.
The physician-patient relationship is based on trust on both sides.
The addictive properties of this medication are due to the body metabolizing it into Meprobamate (a schedule IV, controlled substance).
Carisoprodol was also found to accelerate the affects of other drugs, such as Hydrocodone and Codeine, resulting in greater abuse potential among users.